Idiopathic Pulmonary Fibrosis Market Size, Share, Epidemiology, Forecast, 2030
DelveInsight’s ‘Idiopathic
Pulmonary Fibrosis (IPF) - Market Insights, Epidemiology and Market
Forecast-2030 report delivers an in-depth understanding of the
disease, historical & forecasted epidemiology as well as the market trends
of IPFs in the United States, EU5 (Germany, Spain, Italy, France and
United Kingdom) and Japan.
The Report provides the current treatment
practices, emerging drugs, market share of the individual therapies, current
and forecasted market size of Idiopathic Pulmonary Fibrosis (IPF) from 2017 to
2030 segmented by seven major markets. The Report also covers current treatment
practice/algorithm, market drivers, market barriers and unmet medical needs to
curate best of the opportunities and assess underlying potential of the market.
Idiopathic
Pulmonary Fibrosis (IPF) - Disease Understanding and Treatment Algorithm
Idiopathic Pulmonary Fibrosis (IPF) is a
rare, chronic, progressive fibrosing interstitial pneumonia which is found to
affect the middle-aged and older adults; and affects lung tissue (alveoli in
particular) by either thickening, stiffening, or persistent and progressive
scarring (fibrosis) which increases irreversibly over time. If an individual
has IPF, scarring affects the air sacs, limiting the amount of oxygen that gets
into the blood. With less oxygen in the blood, one can get breathlessness from
everyday activities, like walking. This group of lung disorders is also known
as ‘Diffuse Parenchymal Lung Diseases,’ which is characterized by a broader
umbrella of ‘Interstitial Lung Diseases (IDLs).
The DelveInsight Idiopathic
Pulmonary Fibrosis (IPF) market report gives the thorough understanding
of the Idiopathic Pulmonary Fibrosis by including details such as disease
definition, classification, symptoms, etiology, pathophysiology, diagnostic
trends. It also provides treatment algorithms and treatment guidelines for
Idiopathic Pulmonary Fibrosis in the US, Europe and Japan.
Idiopathic
Pulmonary Fibrosis Epidemiology
The Idiopathic Pulmonary Fibrosis
(IPF) epidemiology division provide the insights about historical and
current patient pool and forecasted trend for every seven major countries. It
helps to recognize the causes of current and forecasted trends by exploring
numerous studies and views of key opinion leaders. This part of the DelveInsight
report also provides the diagnosed patient pool and their trends along with
assumptions undertaken.
The disease epidemiology covered in the
report provides historical as well as forecasted epidemiology (Prevalent cases
of IPF, Age-specific cases, Prevalence by severity and Gender-specific cases
of IPF) scenario of Idiopathic Pulmonary Fibrosis (IPF) in the 7MM covering
United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom)
and Japan from 2017–2030.
According to DelveInsight, the total number
of prevalent cases of Idiopathic Pulmonary Fibrosis (IPF) in 7
MM was found to be 229,170, in the year 2017.
Idiopathic
Pulmonary Fibrosis Drug Chapters
This segment of the Idiopathic
Pulmonary Fibrosis report encloses the detailed analysis of marketed
drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to
understand the clinical trial details, expressive pharmacological action,
agreements and collaborations, approval and patent details, advantages and
disadvantages of each included drug and the latest news and press releases.
Currently, there are two approved drugs in
the market; Esbriet (Pirfenidone) and Ofev (Nintedanib) aims at slowing down
the disease progression through acting like anti-fibrotic mediators. Nintedanib
is a potent intracellular inhibitor of the receptor tyrosine kinases PDGFR,
FGFR, vascular endothelial growth factor receptor (VEGFR) and non-receptor
tyrosine kinases of the Src family; Pirfenidone, on the other, is responsible
for reducing markers of oxidative stress, reducing the proliferation of lung
fibroblasts and their differentiation into myofibroblasts by attenuating key
TGF-β-induced signalling pathways (i.e., Smad3, p38, and Akt), reducing the
expression of TGF-β-induced heat-shock protein 47 (HSP47), which is involved in
processing/secretion of procollagen, and reducing expression of α smooth muscle
actin (α-SMA) and collagen type 1.
Idiopathic
Pulmonary Fibrosis Market Outlook
The Idiopathic
Pulmonary Fibrosis market outlook
of the report helps to build the detailed comprehension of the historic, current
and forecasted trend of the market by analyzing the impact of current therapies
on the market, unmet needs, drivers and barriers and demand of better
technology.
According to DelveInsight, the market of
Idiopathic Pulmonary Fibrosis in 7MM was found to be USD 1,510.4
Million in 2017, and is expected to increase during the course of the
study period (2017–2030). Among the 7MM, the United States accounts for the
largest market size of IPF, in comparison to EU5 (the United Kingdom, Germany,
Italy, France, and Spain) and Japan.
Idiopathic
Pulmonary Fibrosis Drugs Uptake
This section focusses on the rate of uptake
of the potential drugs recently launched in the market or will get launched in
the market during the study period from 2017–2030. The analysis covers market
uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with
the most rapid uptake, reasons behind the maximal use of new drugs and allows
the comparison of the drugs on the basis of market share and size which again
will be useful in investigating factors important in market uptake and in
making financial and regulatory decisions.
Request for full report @https://www.delveinsight.com/sample-request/idiopathic-pulmonary-fibrosis-market
Frequently asked questions:
What is Idiopathic Pulmonary Fibrosis?
Idiopathic Pulmonary Fibrosis (IPF) is a
chronic, progressive disease characterized by the aberrant accumulation of
fibrotic tissue in the lungs parenchyma, associated with significant morbidity
and poor prognosis.
What was the Idiopathic Pulmonary Fibrosis
market size in the 7 major markets (7MM)?
Idiopathic Pulmonary Fibrosis Market Size
was 1,510 Million in the 7MM in 2017
Which geography accounted for the largest
Idiopathic Pulmonary Fibrosis market size?
The US accounted for the largest Idiopathic Pulmonary
Fibrosis market size among the 7MM
What are the Idiopathic Pulmonary Fibrosis
market drivers?
The grant of special regulatory designations,
several therapies in the pipeline from various companies, an increase in the
prevalence of fibrotic diseases are the Idiopathic Pulmonary Fibrosis
market drivers
What are the Idiopathic Pulmonary Fibrosis
market barriers?
The prognosis of patients
with Idiopathic Pulmonary Fibrosis remains poor, lack of accurate
diagnostic procedures and, specific validating biomarkers, Idiopathic
Pulmonary Fibrosis is associated with high mortality rates are the
Idiopathic Pulmonary Fibrosis market barriers
How many companies are developing drugs for
Idiopathic Pulmonary Fibrosis?
MediciNova, FibroGen, Kadmon Corporation,
Promedior, Inc, Galapagos NV are developing drugs for Idiopathic Pulmonary
Fibrosis
Comments
Post a Comment